Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.40 |
| ▸ | RPS6KA1 | Q15418 | 14/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 6/20 | 0.40 |
| ▸ | AKT2 | P31751 | 6/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070921 | 0.82 | SMN1; SMN2 (0.39) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL14031396 | 0.82 | RPS6KA5 (0.40) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL5062965 | 0.81 | RPS6KA5 (0.40) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL14031476 | 0.77 | AKT1 (0.42) | AKT1ROCK1RPS6KA1AKT2SLC2A1 | |
| SCHEMBL13702485 | 0.77 | AKT1 (0.54) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL14031596 | 0.72 | MERTK (0.41) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL4303916 | 0.72 | AKT1 (0.52) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL14031568 | 0.71 | RPS6KA5 (0.47) | AKT1ROCK1RPS6KA1RPS6KA5CYP1A2 | |
| SCHEMBL4290499 | 0.71 | AKT1 (0.53) | AKT1ROCK1RPS6KA1RPS6KA5AKT2 | |
| SCHEMBL5067678 | 0.70 | RPS6KA5 (0.47) | AKT1RPS6KA1RPS6KA5SLC2A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AKT1 5/4885ROCK1 478/4885RPS6KA1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.